Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Company analysis

Company analysis


  • Sort by Product ID
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Shire Company Analysis

    $3,000.00

    PharmaVitae explores Shire’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts

    August 30, 2018
    Find out more

  • Company Analysis: Johnson & Johnson

    $3,000.00

    PharmaVitae explores Johnson & Johnson’s prescription pharmaceutical performance and outlook over 2019–29.

    January 25, 2021
    Find out more

  • Company Analysis: Incyte

    $3,000.00

    PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.

    January 25, 2021
    Find out more

  • JP Morgan Healthcare Conference Preview

    $3,000.00

    PharmaVitae previews companies presenting at the JP Morgan Healthcare Conference to be held in San Francisco over 8–11 January 2018.

    January 10, 2018
    Find out more

  • JP Morgan Healthcare Conference Review

    $3,000.00

    The 2018 JP Morgan Healthcare Conference held in San Francisco over 8–11 January 2018 was light on big news and deals, but PharmaVitae picked up on key themes for some of the presenting companies in our coverage universe, which are all experiencing and/or pursuing a change of scene and pace in dealmaking activity.

    January 18, 2018
    Find out more

  • Company Analysis: BioMarin

    $3,000.00

    PharmaVitae explores BioMarin’s prescription pharmaceutical performance and outlook over 2019–29.

    January 25, 2021
    Find out more

  • Acorda Company Analysis

    $3,000.00

    PharmaVitae explores Acorda’s prescription pharmaceutical performance and outlook over 2017–27.

    February 9, 2018
    Find out more
  • big_pharma_diversification_strategies_cover

    Big Pharma Diversification Strategies

    $2,995.00

    Pressures ranging from continually declining revenues as a result of generics and impending biosimilars launches, to slow R&D productivity and market access restrictions could cause the Big Pharma peer set to evaluate business opportunities beyond pharmaceuticals.

    March 4, 2018
    Find out more
  • M&A Analysis

    M&A Outlook 2018

    $3,000.00

    PharmaVitae explores the rationale for accelerated dealmaking in 2018, earmarking companies touted for M&A activity, and details 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.

    April 24, 2018
    Find out more

  • Japan Pharma Outlook 2027

    $3,000.00

    PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* through analysis and in-house sales forecasts for more than 320 products.

    July 2, 2018
    Find out more
  • M&A Analysis

    M&A Analysis 2018

    $3,000.00

    PharmaVitae has launched the M&A Outlook 2018 report, click to view the 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.

    April 24, 2018
    Find out more

  • Under the Radar Takeover Targets

    $3,000.00

    Following on from its M&A Outlook 2018 report, PharmaVitae highlights under the radar takeover targets that are potentially attractive to companies on the prowl for acquisitions.

    July 20, 2018
    Find out more

  • Company Analysis: Vertex

    $3,000.00

    PharmaVitae explores Vertex’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

    January 25, 2021
    Find out more

  • The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)

    $3,000.00

    This decade has seen the emergence of therapies harnessing the immune system to treat cancer.

    October 1, 2018
    Find out more

  • Company Analysis: GlaxoSmithKline

    $3,000.00

    PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    January 25, 2021
    Find out more
Page 4 of 5
Page 4 of 512345
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top